Woodford Investment Management Ltd

Person Signing this Report on Behalf of Reporting Manager:

Explanatory Note: This amendment is being filed to correct errors in the Voting Authority None column of the Information Table as originally filed. The Reporting Manager ("WIM") is the investment manager of various funds (the "W Funds"), including the Other Included Managers set forth herein ("13F Funds"), and has defined investment discretion and, except as detailed below and in the Information Table ("Table"), shared voting authority with respect to the securities held by W Funds reported herein. With respect to Evofem Biosciences, Inc. ("EB"), LF Woodford Equity Income Fund ("LF") and Omnis Income & Growth Fund own shares of EB common stock ("E Stock") (each an "E Fund" and together the "E Funds"). The E Funds have each delivered to EB a duly executed irrevocable proxy appointing any designee of EB as their respective sole and exclusive attorney and proxy to vote at every meeting of EB stockholders with respect to all shares of E Stock owned by such E Fund in excess of 19.5% of the then outstanding shares of E Stock (the "E Threshold") in the same proportion as shares voted by all other stockholders (excluding such E Fund) voting on or consenting to such matters. Accordingly, each E Fund has voting power (which it shares with WIM) only up to and including the E Threshold. LF holds E Stock above the E Threshold, thus voting power above the E Threshold is reported as "none" in Column 8 of the Table. For this calculation, the total outstanding EB shares used was 25,867,248 shares outstanding as reported in EB's Form 10-Q, filed with the SEC on 11/7/18. Please refer to the Form of Voting Agreement, incorporated by reference to Exhibit 4.10 of EB's Form S-4 (No. 333-221592) filed on 11/15/17 and WIM's Schedule 13G/A with respect to the E Stock filed by WIM on 2/14/19, for more information. With respect to Autolus Therapeutics plc ("AT"), four W Funds (including LF and Woodford Patient Capital Trust Plc ("PCT") have executed irrevocable proxies appointing WIM as their sole and exclusive attorney and proxy to vote at every meeting of shareholders of AT and exercise all rights with respect to all capital stock of AT, including ordinary shares ("A Shares"), beneficially owned by such funds ("A Proxy Shares"). WIM executed an irrevocable proxy appointing any designee of AT as the sole and exclusive attorney and proxy of WIM to represent WIM and to vote at every meeting of shareholders of AT and exercise all rights with respect to all A Proxy Shares, which when added to A Shares beneficially owned by a segregated account managed by WIM ("WEST"), Quilter Investors UK Equity Income II Fund ("Quilter") and Arix Bioscience plc ("AB"), are in excess of 9.99% of the then outstanding capital stock of AT (the "A Threshold") in the same proportion as the shares voted by all other stockholders (excluding WIM and Quilter) voting on such matters. Accordingly, (i) no W Fund that has executed a voting proxy in favor of WIM has voting control over A Shares held by it, and for those W Funds who are 13F Funds (LF and PCT), such voting control is reported as "none" in Column 8 of the Table, (ii) WIM has sole voting power with respect to A Proxy Shares, which when added to the A Shares held by AB, WEST and Quilter, are at or below the A Threshold, and such voting control is reported as "sole" in Column 8 of the Table and (iii) WIM has no voting power with respect to all other A Shares held by the W Funds (which voting power resides solely with AT), and such voting control is reported as "none" in Column 8 of the Table. For purposes of this calculation, (x) the total outstanding A Shares used was 40,416,182 shares of outstanding ordinary shares as of 9/30/18 as reported in AT's Annual Report on Form 20-F, filed with the SEC on 11/23/18, (y) the total outstanding A Shares owned by Quilter was 167,504 shares as of 12/31/18 and (z) the total A Shares owned by AB was 3,161,533 shares, as disclosed in the AT Schedule 13D filed by AB on 7/6/18.

Other Included Managers (4):